ResMed(US:RMD) ZACKS·2025-04-23 23:00Core Insights - ResMed reported $1.29 billion in revenue for the quarter ended March 2025, a year-over-year increase of 7.9% and an EPS of $2.37 compared to $2.13 a year ago, exceeding the Zacks Consensus Estimate of $1.28 billion by 0.53% [1] Financial Performance - The company delivered an EPS surprise of 0.42%, with the consensus EPS estimate being $2.36 [1] - Shares of ResMed have returned -3.3% over the past month, while the Zacks S&P 500 composite changed by -6.6% [3] Regional Performance - U.S., Canada, and Latin America - Devices: $422.70 million, a change of +5.9% year over year, compared to the average estimate of $426.47 million [4] - U.S., Canada, and Latin America - Masks and other: $326.70 million, representing a +13.4% change year over year, exceeding the estimate of $318.76 million [4] - Combined Europe, Asia, and other markets - Total: $381.30 million, a +5.5% change year over year, compared to the estimate of $377.86 million [4] - Combined Europe, Asia, and other markets - Devices: $253.50 million, a +6.1% change year over year, exceeding the estimate of $249.75 million [4] - Combined Europe, Asia, and other markets - Masks and other: $127.70 million, a +4.2% change year over year, slightly below the estimate of $128.11 million [4] - U.S., Canada, and Latin America - Total: $749.30 million, a +9% change year over year, compared to the estimate of $745.22 million [4] Global Revenue Breakdown - Global revenue - Total Sleep and Breathing Health: $1.13 billion, a +7.8% change year over year, exceeding the estimate of $1.12 billion [4] - Global revenue - Residential Care Software: $161.20 million, a +8.9% change year over year, slightly above the estimate of $161.15 million [4] - Global revenue - Total Devices: $676.20 million, a +6% change year over year, in line with the estimate of $676.22 million [4] - Global revenue - Total Masks and other: $454.40 million, a +10.6% change year over year, exceeding the estimate of $446.86 million [4]